HEM.V - Hemostemix Inc.

TSXV - TSXV Real Time Price. Currency in CAD
0.1300
0.0000 (0.00%)
At close: 03:51PM EDT
Stock chart is not supported by your current browser
Previous Close0.1300
Open0.1300
Bid0.1250 x 0
Ask0.1300 x 0
Day's Range0.1300 - 0.1300
52 Week Range0.1150 - 0.3750
Volume10,170
Avg. Volume61,912
Market Cap10.542M
Beta (5Y Monthly)0.56
PE Ratio (TTM)N/A
EPS (TTM)-0.0700
Earnings DateSept 27, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.96
  • CNW Group

    IIROC Trading Resumption - HEM

    Trading resumes in:

  • Newsfile

    Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company

    Calgary, Alberta--(Newsfile Corp. - May 2, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has engaged Chris McNorgan, PhD, to drive a license agreement of NCP-01 with a company who is pursuing neural electrode-based brain intervention. Dr. McNorgan's research - the neural bases of cognition, including AI methods to decode and simulate neocortical representations of knowledge and motor intention - is directly ...

  • CNW Group

    IIROC Trading Halt - HEM

    The following issues have been halted by IIROC:

  • Newsfile

    Hemostemix' Second Round Interviews with Executive Vice President Business Development Candidates

    Calgary, Alberta--(Newsfile Corp. - April 3, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is completing a second round of interviews with candidates who may join the company as Executive Vice President, Business Development. The EVP Business Development will be responsible for building and leading a team focused on the following:The sale of Tranch 1 - 500 ACP treatment convertible debentures at USD ...

  • Newsfile

    Hemostemix Engages Montreal's RobboDesign to SEO Its Website to Engage with 236 Million Peripheral Arterial Disease and Critical Limb Ischemia Patients Globally

    Calgary, Alberta--(Newsfile Corp. - March 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has engaged Montreal's RobboDesign to revise and search engine optimize its website, to engage with critical limb ischemia "CLI" and peripheral arterial disease "PAD" patients, globally. The purpose of the revisions are to engage with CLI and PAD patients, to provide them with ACP-01 as limb saving treatment, ...

  • Newsfile

    Hemostemix Closes $762,400 of The Unit Private Placement

    Calgary, Alberta--(Newsfile Corp. - March 21, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that it has closed its first tranche of its previously announced non-brokered private placement of units ("Units") for gross proceeds of $762,400 (the "Offering"). The Offering consisted of the issuance of an aggregate of 3,812,000 Units at a price of $0.20 per Unit.Each Unit consists of one common share in ...

  • Newsfile

    Hemostemix Unit Offering Repriced

    Calgary, Alberta--(Newsfile Corp. - March 8, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) announces it is repricing its offering of 14 Million Common Share Units to $0.20 each. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.65 per ...

  • Newsfile

    Hemostemix Offers up to 500 6% Convertible Debentures, Convertible into an ACP-01 Therapeutic Production Slot that is Subject to Compassionate Exemption from Regulatory Approval

    Calgary, Alberta--(Newsfile Corp. - March 7, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("HEM" or the "Company") is pleased to announce it is selling up to 500 five-year 6% unsecured convertible debentures ("CD") at USD $35,000 each. The CD can be converted into one of 500 ACP-01 therapeutic production slots ("TPS"), subject to patients' compassionate exemption from regulatory approval, or is convertible into Common Shares of Hemostemix as ...

  • Newsfile

    Hemostemix Announces Unit Private Placement

    Calgary, Alberta--(Newsfile Corp. - February 1, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a non-brokered private placement of up to 14 Million Units priced at $0.24 each, closing in tranches. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each full Warrant entitling the holder to acquire one Common Share at ...

  • Newsfile

    The Force Family Office Engaged by Hemostemix

    Calgary, Alberta--(Newsfile Corp. - January 31, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is plugged into the largest network of family offices in the United States via its agreement with the Force Family Office. In 2022, The Force Family Office hosted more than 150 events, connecting family offices with private and public companies for co-investment. Founded in 2020 by Steven Saltzstein ...

  • Newsfile

    Hemostemix' "Your Fountain of Youth" Trademark Granted by Switzerland

    Calgary, Alberta--(Newsfile Corp. - January 30, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its Trademark, Your Fountain of Youth, was granted protection in Switzerland by its Trademark Office. Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., has received a Statement of Grant of Protection from the Swiss Trademark Office, and notice of the grant from the World Intellectual Property Organization."Your

  • Newsfile

    Hemostemix' "Your Fountain of Youth" Trademark Granted by Japan Patent Office

    Calgary, Alberta--(Newsfile Corp. - January 26, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Japan Patent Office issued Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., a trademark registration certificate for Your Fountain of Youth. "Your Fountain of Youth explains the benefit of leveraging your synergetic cell population as ACP-01 and it explains Hemostemix' business model," stated Thomas Smeenk,

  • Newsfile

    Hemostemix Wins Arbitration Decision

    Calgary, Alberta--(Newsfile Corp. - January 24, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Arbitrator has dismissed Dr. Burchardt's claims for compensation and damages against the Company, set aside the Change of Control Agreement on the grounds that it was entered into in violation of Dr. Burchardt's duties as a director under sections 120 and 122 of the Business Corporations Act (Alberta), ...

  • GlobeNewswire

    InvestmentPitch Media Video Discusses Hemostemix and its Hiring of 4 Biotechnologists to Re-Establish Production of ACP-01 in Montreal and Applying for Grants to Fund Up to 75% of 5-Year Expenses

    VANCOUVER, British Columbia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0), an autologous stem cell therapy company, is hiring four biotechnologists to re-establish the company’s production of ACP-01 in Montreal. This staffing requirement arose because of the recently announced $250,000 Letter of Commitment for funding from the McGill University Health Centre Foundation to fund $250,000 of clinical trial expenses of a phase II double blind randomized clini

  • Newsfile

    Hemostemix Hiring 4 New Biotechnologists in Montreal and Appling for Grants to Fund Up To 75% of 5-Year Costs

    Calgary, Alberta--(Newsfile Corp. - January 23, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is hiring four new biotechnologists to re-establish the Company's production of ACP-01 in Montreal. The Company is hiring an experienced autologous stem cell therapy Manufacturing Manager, a Quality Control Manager, and two Manufacturing Technologists. Coincidentally, Hemostemix has applied for Federal and Provincial grant fundin

  • GlobeNewswire

    InvestmentPitch Media Video Discusses Hemostemix and its $250,000 in Funding from McGill University Health Centre Foundation for Clinical Trial of ACP-01

    VANCOUVER, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF), an autologous stem cell therapy company, has received a $250,000 Letter of Commitment for funding from the McGill University Health Centre (MUHC) Foundation. Under the Letter of Commitment, the MUHC Foundation will fund $250,000 of the clinical trial expenses and partner with Hemostemix, Dr. Nadia Giannetti and Dr. Renzo Cecere to complete a phase II double blind randomized clinical trial of

  • Newsfile

    Hemostemix Announces Letter of Commitment, Non-Dilutive Funding Structure and $250,000 of Funding by the McGill University Health Centre Foundation

    Calgary, Alberta--(Newsfile Corp. - January 19, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it has received a $250,000 Letter of Commitment for funding from the McGill University Health Centre (MUHC) Foundation. The Letter of Commitment confirms that the MUHC Foundation will fund $250,000 of the clinical trial expenses and partner with Hemostemix, Dr. Nadia Giannetti and Dr. Renzo Cecere to complete a phase II double ...

  • Newsfile

    Hemostemix Issued 'Your Fountain of Youth' Trademark by Cyprus

    Calgary, Alberta--(Newsfile Corp. - December 8, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Office of the Registrar of Trademarks, Republic of Cyprus, issued Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., a trademark registration certificate for Your Fountain of Youth. The Trademark is registered initially for 10 years. The Company's has a right to renew for additional 10-year ...

  • Newsfile

    Hemostemix Thanks Neim Malo, Beefstro's Founder, for His ACP-01 Testimonial Interview

    Calgary, Alberta--(Newsfile Corp. - November 30, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") thanks Mr. Neim Malo, founder of Beefstro's, for his ACP-01 testimonial interview now available on YouTube (https://youtu.be/1ezFC0oIU9s).Cannot view this video? Visit:https://www.youtube.com/watch?v=1ezFC0oIU9sMr. Neim Malo is an award-winning restauranteur, and founder of Bistro's, "Where the Beef Goes On!" Currently writing a book, My Illegal Heart, M

  • Newsfile

    Hemostemix Thanks Six-Time Grammy Award Winner, Howie Lindeman, for his ACP-01 Testimonial Interview

    Calgary, Alberta--(Newsfile Corp. - November 17, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to thank six-time Grammy Award Winner, Mr. Howie Lindeman, for his ACP-01 testimonial interview (https://www.youtube.com/watch?v=KTuq3Oy7WU0) now available on YouTube.Cannot view this video? Visit:https://www.youtube.com/watch?v=KTuq3Oy7WU0Mr. Howard "Howie" Lindeman started at The Record Plant recording studios NYC in 1974. His career as a Pr

  • Newsfile

    Hemostemix Announces Advancements in Its Automation of Production

    Calgary, Alberta--(Newsfile Corp. - November 15, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the continued evolution of its patented Automated Cell Therapy System (ACTS). The Hemostemix ACTS is designed to scale our autologous stem cell therapy processes by leveraging robotic-material-handling and parallel-processing efficiencies, duplicating our manual methods of angiogenic cell precursor (ACP-01) production. ACTS will sc

  • Newsfile

    Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials

    Calgary, Alberta--(Newsfile Corp. - October 26, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Medicine and Clinical Trials. Dr. Giannetti and Dr. Cecere will assist Hemostemix with financing introductions and due diligence responses; help position ACP-01 as a candidate to be the first-to-patient autologous stem cell treatment of heart disease; design

  • Newsfile

    Hemostemix Announces Presentation to the Emerging Growth Conference

    Calgary, Alberta--(Newsfile Corp. - October 25, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") invites shareholders, brokers and financial advisors, institutional investors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference on Wednesday, October 26th at 12:00 EDT. Attendees may use the following link to attend:(https://goto.webcasts.com/starthere.jsp?ei=1575084&tp_key=b452034330&sti=hmtxf).ABOUT HEMOSTEMIXHemostem

  • GlobeNewswire

    Presenting on the Emerging Growth Conference on October 26 Register Now

    Niche Companies in, Technology, Transportation, Biotech, Mining, MedTech, Logistics, and HealthcareMIAMI, Oct. 25, 2022 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 43rd Emerging Growth Conference on October 26, 2022. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong manageme